findmyKOL

Helmy Siragy, MD

Basic profile

University of Virginia Health System

ORCIDNPI
RegionCharlottesville, VA · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2020findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2015Online presenceNot yet checkedPaymentsNone reportedNIH funding1990–2020Why? →

Helmy Siragy is an Endocrinology/Metabolic physician affiliated with University of Virginia Health System. OpenAlex indexes 233 publications with 9,857 citations (h-index 55).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
233publications

Distinct works indexed by OpenAlex, matched via ORCID.

9,857citations

Total citations across indexed works.

55h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
8NIH grants · 1990–2020

Federally funded research awards.

View funding

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    58%
    Insulin Analog35.5%
    Lantus Solostar41%Novolog Flexpen18%Humalog Kwikpen U-10013%Levemir Flexpen9%Insulin Lispro Kwikpen U-1007%Lantus6%Basaglar Kwikpen U-1005%
    Part D<11 patients
    Biguanide (metformin)7.2%
    Metformin Hcl62%Metformin Hcl Er38%
    Part D<11 patients

    + 4 more classes in this area

  • Cardiovascular

    28.6%
    Statin9%
    Atorvastatin Calcium69%Simvastatin31%
    Part D<11 patients
    Thiazide diuretic6.5%
    Hydrochlorothiazide100%
    Part D15 patients

    + 3 more classes in this area

  • Hormonal (systemic)

    13.4%
    l-Thyroxine11.2%
    Levothyroxine Sodium68%Synthroid32%
    Part D<11 patients
    l-Triiodothyronine2.2%
    Liothyronine Sodium100%
    Part D<11 patients
Where care is delivered (Part B)50.5% facility · 49.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

8 NIH research awards on record, funded 19902020 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”